Home › Merck Announces Initial Results for KEYTRUDA (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
 

Keywords :   


Merck Announces Initial Results for KEYTRUDA (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress

2015-11-21 22:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with three other immunotherapies epacadostat, IMLYGICTM (talimogene laherparepvec), and ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results international research society

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.05The rise of Sweden's super rich
06.05Eurotunnel says no queues with new travel system
05.05ELF Beauty Teams with Billie Jean King to Change the Board Game to Support Inclusivity
05.05Target Faces Lawsuit Over Sunscreen Coral Bleaching Claims
05.05Goops Latest Launch & Hain Celestial Streamlines Portfolio
05.05The Summer of Sister Golden Hair
05.05Persil Laundry Detergent Rebrands
05.05Weekly Recap: Carefree Adds Pads to Lineup, Soft N Dry Secures Private Label Sales Network ...
More »